KRYS240920C250000
- 5.76
- 0.000.00%
Krystal Biotech Newsroom
Krystal Biotech Insider Sold Shares Worth $9,888,276, According to a Recent SEC Filing
Krystal Biotech(KRYS.US) 10% Shareholder Sells US$9.89 Million in Common Stock
$Krystal Biotech(KRYS.US)$ 10% Shareholder Krishnan Krish S sold 50,000 shares of common stock on Sep 12, 2024 at an average price of $197.7655 for a total value of $9.89 million. This transaction
Krystal Biotech to Present at 2024 Cantor Global Healthcare Conference
Form 144 | Krystal Biotech(KRYS.US) Director Proposes to Sell 4.97 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Sep 12, $Krystal Biotech(KRYS.US)$ Director KRISH KRISHNAN intends to sell 25,000 shares of its common stock on Sep 12, with a total market value of approximately $4.97
Here's How Much You Would Have Made Owning Krystal Biotech Stock In The Last 5 Years
GSK's HSV Vaccine Study Fails to Meet Primary Efficacy Goal
VRDN Stock Soars as Eye Disorder Study Meets Primary Endpoints
Domino's Pizza To $510? Here Are 10 Top Analyst Forecasts For Wednesday
Krystal Biotech Is Maintained at Buy by Stifel
Express News | Krystal Biotech Inc : Stifel Raises Target Price to $220 From $204
How Is The Market Feeling About Krystal Biotech?
Stifel Maintains Krystal Biotech(KRYS.US) With Buy Rating, Announces Target Price $204
Stifel analyst Dae Gon Ha maintains $Krystal Biotech(KRYS.US)$ with a buy rating, and sets the target price at $204.According to TipRanks data, the analyst has a success rate of 46.0% and a total
IMVT Stock Up on Upbeat Data From Graves' Disease Study of Batoclimab
Novartis to License VYGR's Capsid for Gene Therapy in Neurology
Krystal Biotech to Present at H.C. Wainwright 26th Annual Global Investment Conference
Surging Earnings Estimates Signal Upside for Krystal Biotech (KRYS) Stock
Krystal Biotech Stock Surges 21.9% in 3 Months: More Room to Grow?
TD Cowen Maintains Krystal Biotech(KRYS.US) With Buy Rating, Maintains Target Price $208
TD Cowen analyst Ritu Baral maintains $Krystal Biotech(KRYS.US)$ with a buy rating, and maintains the target price at $208.According to TipRanks data, the analyst has a success rate of 48.0% and a
Krystal Biotech (KRYS) Receives a Buy From TD Cowen
Cantor Fitzgerald Reiterates Overweight on Krystal Biotech